CXCL8 and cancer: To try to identify alternative pathways regulated by miR-942, we studied the expression of pro-angiogenic cytokines that have been previously described to confer resistance to sunitinib in cancer patients, including MMP-9, TNF-α [10] and IL-8 [19].